SCHEMBL4059122

SCHEMBL4059122

CCOC(=O)C(=CI)C(C)(C)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.41
GLO1 Q04760 1/20 0.41
ALDH1A1 P00352 4/20 0.37
CYP2D6 P10635 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 3/20 0.36
HSD17B10 Q99714 1/20 0.36
TSHR P16473 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
ALOX15 P16050 1/20 0.34
MGAM O43451 1/20 0.34
GAA P10253 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
SOAT1 P35610 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34
CYP2C9 P11712 2/20 0.34
MAPT P10636 3/20 0.33
HCAR2 Q8TDS4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059117 1.00 NPSR1 (0.41) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL4052216 0.84 NPSR1 (0.38) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL10486427 0.82 GLO1 (0.44) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL4060396 0.75 MEN1 (0.47) ALDH1A1CYP2D6SMN1; SMN2LMNATSHR
SCHEMBL4060402 0.75 MEN1 (0.47) ALDH1A1CYP2D6SMN1; SMN2LMNATSHR
SCHEMBL4060291 0.75 DHODH (0.43) NPSR1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4060296 0.75 DHODH (0.43) NPSR1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL20691515 0.73 ALDH1A1 (0.43) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL4057737 0.72 GAA (0.43) ALDH1A1CYP2D6LMNATSHRMEN1
Tert-Butanol SCHEMBL11267233 0.72 ALDH1A1 (0.48) NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009110655-A1 NOVEL BETA SUBSTITUTED MORITA-BAYLIS-HILLMAN DERIVATIVES SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION (KR) 2009-09-11 WO claimed
WO-2009110655-A1 NOVEL BETA SUBSTITUTED MORITA-BAYLIS-HILLMAN DERIVATIVES SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION (KR) 2009-09-11 WO disclosed
US-7405309-B2 Pyranone derivatives useful for treating cancer CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2008-07-29 US disclosed
US-20070167515-A1 Pyranone derivatives useful for treating cancer CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167515-A1 Pyranone derivatives useful for treating cancer HCCS, PDXK, CBR3 NPSR1 3365/4885GLO1 1291/4885ALDH1A1 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.